865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. (23rd October 2018) - Petrylak, D P; Sternberg, C N; Drakaki, A; de Wit, R; Nishiyama, H; Necchi, A; Castellano, D; Bamias, A; Chi, K N; van der Heijden, M S; Matsubara, N; Hussain, S; et al.